Abstract
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are able to carry genetic and protein goods to mediate the interaction between MSCs and target cells. Recently, more and more researches have focused on the therapeutic role of MSC-EVs in chronic respiratory diseases. In this review, we summarize the cumulative strategies and mechanisms of MSC-EVs in treating chronic respiratory diseases. This review suggests that MSC-EVs may serve as a novel cell-free-based therapy for chronic respiratory diseases, including COPD, asthma, pulmonary fibrosis, and pulmonary arterial hypertension. In current studies of chronic respiratory diseases, umbilical cord and bone marrow are main sources of MSC-EVs, while adipose tissue, lung, and induced pluripotent stem cells are also applied. Isolation methods of MSC-EVs in treating chronic respiratory diseases involve ultracentrifugation, exosome extraction kits and anion-exchange chromatography. Intratracheal delivery and intravenous administration are the most widely used routes of MSC-EVs. MSC-EVs are able to transfer microRNAs and protein to target cells and further magnify the therapeutic effects.
Introduction
Chronic respiratory diseases are diseases of the airways and other structures of the lung, mainly including chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases and pulmonary hypertension (World Health Organization, 2021). Chronic respiratory diseases remain leading causes of death and disability. It is estimated that 4 million people per year die from chronic respiratory diseases worldwide (Forum of International Respiratory Societies, 2017; Soriano et al., 2020). Considering the heavy social burden from chronic respiratory diseases, effective prevention and treatment measures are urgently needed.
Mesenchymal stem cells (MSCs) refer to a group of cells from bone marrow, fat and umbilical cord, which have the ability of adherent growth. Currently, MSCs are commonly used in cell therapy due to important potentials of proliferation, differentiation and immune regulation (Weiss and Dahlke, 2019). Extracellular vesicles (EVs) are vesicles with membrane structure released by cells in the state of activation, injury or apoptosis; According to the diameter of vesicles, they can be divided into apoptotic bodies, micro vesicles, and exosomes (Shao et al., 2018). A growing number of studies have shown that EVs mediate intercellular targeted regulation by transferring different substances (including protein, DNA, microRNA, lncRNA, circRNA and mRNA) (Lasda and Parker, 2016; Li et al., 2019; Vagner et al., 2019; Vu et al., 2020; Vilaca et al., 2021). Importantly, compared with other commonly used drug delivery carriers (such as liposomes), EVs have the advantages of high internal targeting ability, low immunogenicity, high modification flexibility and high biological barrier permeability, which opens up a new field for modern drug delivery (Herrmann et al., 2021).
MSCs can produce a large number of EVs. MSC-EVs can mediate the interaction between MSCs and target cells through delivering genetic and protein goods, and this targeting mode has attracted great attention in the treatment of chronic kidney diseases, cardiovascular diseases, neurological diseases and tumor (Eirin and Lerman, 19792021; Fu et al., 2020; Tran et al., 2020; Pucci et al., 2021)) MSC-EVs can play a therapeutic role similar to MSCs, and MSC-EVs are easier to store and make dosage forms; Meanwhile, MSC-EVs avoid some limitations of cell therapy, such as embolization and tumorigenesis (Shi et al., 2021). The potential anti-inflammatory effect of MSC-EVs has been proved in several previous studies related to acute lung injury (Monsel et al., 2015; Ahn et al., 2018; Khatri et al., 2018). Recently, more and more researches have focused on the therapeutic role of MSC-EVs in chronic respiratory diseases. In this review, we summarize the cumulative strategies and mechanisms of MSC-EVs in treating chronic respiratory diseases, which may provide novel therapeutic alternatives for chronic respiratory diseases.
Sources of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Therapeutic Applications of Chronic Respiratory Diseases
Umbilical cord (UC) and bone marrow (BM) are main sources of MSC-EVs in treating chronic respiratory diseases, while other relatively rare sources include adipose tissue, lung, and induced pluripotent stem cells (iPSCs).
UC is an appropriate source of MSC-EVs, with the advantage of non-invasion in the collecting process of UC (de Faria et al., 2012). BM may be suboptimal, as BM-MSCs have shown decreased differentiation potential and BM samples are rather difficult in acquisition (Sergejeva et al., 2004). Of note, the use of adipose tissues to harvest MSCs has become common due to its unique advantages such as easy access, great texture and rapid expansion in vitro (Bertassoli et al., 2013; Jalali and Rabiee, 2016). However, few studies have investigated the therapeutic functions of MSC-EVs from adipose tissues in chronic respiratory diseases. Lung is another source of MSC-EVs. Cells derived from human lung allografts present a multipotent mesenchymal cell population, which is locally resident in the human adult lung and has extended life span in vivo; And multipotency of these cells was proved by their capacity to differentiate into adipocytes, chondrocytes, and osteocytes (Lama et al., 2007). iPSCs are also sources of MSC-EVs, and MSC-EVs from iPSCs can be utilized for drug delivery by loading with proteins (Yuan et al., 2017). iPSCs maintain the developmental potential to differentiate into advanced derivatives of all three primary germ layers, which provides a novel direction of regenerative medicine.
Solation Methods of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Therapeutic Applications of Chronic Respiratory Diseases
Methods used to isolate MSC-EVs in treating chronic respiratory diseases involve ultracentrifugation (UCF), exosome extraction kits and anion-exchange chromatography.
UCF is the current gold standard and the most studied methods for EV isolation (Momen-Heravi, 2017). The centrifugal speed for microvesicles is 10,000–60,000 g, while 100,000–200,000 g for exosomes (Borges et al., 2013). However, UCF is time-consuming and isolation outcomes are also highly dependent on speed, rotor type as well as temperature (Livshits et al., 2015). Also, UCF could lead to aggregated EVs after pelleting (Linares et al., 2015). Exosome extraction kits are emerging tools for exosome isolation. One previous study demonstrated that ultracentrifugation and exosome extraction kits are two complementary approaches allowing the detection of different proteoforms with various abundance and purity levels (Gemoll et al., 2020). Thereby, combined isolation methods may be optional to consider in future studies. Anion-exchange chromatography is a scalable protocol developed by Kim et al., in 2016 (Kim et al., 2016). They found that most of the protein from EVs in the harvested medium was bound to an anion exchange resin but that little bound to a cation exchange resin. Besides above mentioned methods, additional techniques or combinations of techniques have been developed to isolate EVs including field-flow fractionation, variations on size exclusion chromatography, microfiltration, asymmetric flow field-flow fractionation, field-free viscoelastic flow, tangential flow filtration and variations thereon, alternating current electrophoretics, deterministic lateral displacement arrays, fluorescence-activated sorting, novel immunoisolation or other affinity isolation technologies etc. (Théry et al., 2018)
Therapeutic Strategies of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Treating Chronic Respiratory Diseases
The dose of MSC-EVs varies in different disease models. Most studies measured total protein amount using various colorimetric assays to indirectly suggest the particle number of EVs. In vivo, 15–100 μg (protein) is the commonly used EV dose for treating mouse or rat models; while 2–40 μg/ml is the usual treatment dose for studies in vitro. Some studies used absolute particle count or MSC number to measure EV treatment dose. The absolute particle count of EVs ranges from 2×107 to 2×1010in vivo.
Intratracheal delivery and intravenous administration are main routes of MSC-EVs in the treatment of chronic respiratory diseases. Compared with intravenous administration, intratracheal administration is a more direct and accurate treatment mode (Chen et al., 2021). An intraperitoneal route could be selected based on its advantages for multiple or daily treatments of EVs (Maremanda et al., 2019). Details of therapeutic strategies of MSC-EVs in treating chronic respiratory diseases are demonstrated in Table 1.
TABLE 1
| References | Year | Disease | EV source | Isolation method | Therapeutic strategy | Mechanisms |
|---|---|---|---|---|---|---|
| Ridzuan et al. (2021) | 2021 | COPD | Human UC-MSCs | UCF | In vivo: EVs from 2.5 × 106 MSCs over 72 h per rat; once; intratracheal delivery | EVs reduce the pulmonary inflammation by the expression of PRKCZ, and NF-κB subunits p65 and p50 |
| Maremanda et al. (2019) | 2018 | COPD | Mouse MSCs | Norgen Biotek kit | In vivo: 15 μg (protein) EVs per mouse; daily for 10 days; intraperitoneal route In vitro: not reported | EVs protect cigarette smoke-induced inflammation and mitochondrial dysfunction |
| Dong et al. (2021) | 2021 | Asthma | Human UC-MSCs | exoEasy Maxi Kit (Qiagen) | In vivo: 100 μg (protein) EVs per mouse; once; intratracheal delivery In vitro: 10, 20, 40 μg/ml EVs added to macrophages for 24 h | EVs inhibit inflammation by reshaping macrophage polarization via inhibition of TRAF1 |
| Fang et al. (2020a) | 2020 | Asthma | Human iPSC-MSCs | Anion-exchange chromatography | In vivo: 1.5×1010 EVs per mouse; once; intravenous administration In vitro: 5×108 EVs added to 3×105 macrophages | EVs ameliorate Th2-dominant allergic airway inflammation through immunoregulation on pulmonary macrophages |
| Fang et al. (2020b) | 2020 | Asthma | Human iPSC-MSCs | Anion-exchange chromatography | In vivo: 2×1010 EVs per mouse; once; intravenous administration In vitro: 5, 40 μg/ml EVs added to ILC2 for 48 h | EVs prevent ILC2-dominant allergic airway inflammation by transferring miR-146a-5p |
| Du et al. (2018) | 2018 | Asthma | Human BM-MSCs | UCF | In vitro: EVs from 1 × 105 MSCs over 48 h added to 1 × 106 PBMCs for 48 h | EVs upregulate IL-10 and TGF-β1 in PBMCs, and promote proliferation and immune-suppression capacity of Tregs |
| Zhang et al. (2021) | 2021 | Pulmonary fibrosis | Rat BM-MSCs | UCF | In vivo: 100 μg (protein) EVs per rat; once; intravenous administration | EVs reverse epithelial mesenchymal transition through Wnt/β-catenin signaling |
| Zhou et al. (2021) | 2021 | Pulmonary fibrosis | Human BM-MSCs | UCF | In vivo: 100 μg (protein) EVs per mouse; once; intravenous administration In vitro: 10 μg EV added to 3–5x105 fibroblast for 24 h | EVs block fibroblast activation and suppress SOX4, DKK1 expression by transferring miR-186 |
| Villamizar et al. (2021) | 2020 | Cystic fibrosis | Human BM-MSCs | UCF | In vitro: 5×1010 EVs added to 104 HuBECs for 48 h | EVs deliver a packaged zinc finger activator to HuBECs and activate CFTR |
| Xu et al. (2020) | 2020 | Pulmonary fibrosis | Human UC-MSCs | Exoquick exosome precipitation solution (System | In vivo: unknown dose; every 4 days; intravenous administration In vitro: not reported | EVs decrease collagen I and fibronectin, and improve pulmonary function |
| Yang et al. (2020) | 2020 | Pulmonary fibrosis | Human UC-MSCs | Biosciences) | In vivo: 100 μg (protein) EVs per mouse; every 4 days; intravenous administration | EVs inhibit epithelial mesenchymal transition activated by the TGF-β1/Smad2/3 signaling pathway |
| Wan et al. (2020) | 2020 | Pulmonary fibrosis | Human BM-MSCs | UCF | In vivo: 100 μg (protein) EVs per mouse; once; intravenous administration In vitro: 10 μg EV added to 3–5x105 fibroblast for 24 h | EVs suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via carrying miR‐29b‐3p |
| Gao et al. (2020) | 2020 | Pulmonary fibrosis | Rat AMSCs | UCF | In vivo: 2.5–2.8×1010 EVs per rat; once; intratracheal delivery In vitro: 1×109 EVs added to 1×106 ATII cells for 6 h | EVs inhibit TGF-bRI by transferring let-7d-5p |
| Zulueta et al. (2018) | 2018 | Cystic fibrosis | Human lung MSCs | UCF | In vitro: EVs from 3 × 106 MSCs over 48–72 h added to 2.5 × 105 HBECs for 30 h | EVs upregulate PPARγ, a transcription factor controlling anti-inflammatory and antioxidant mechanisms via NF-kB and HO-1 |
| Klinger et al. (2020) | 2020 | PAH | MSCs | UCF | In vivo: 100 mg/kg EVs per rat; three times; intravenous administration In vitro: 0, 2, 5, and 10 μg/ml EVs added to macrophages for 48 h | EVs decrease lung macrophages, increase the ratio of M2/M1 macrophages, normalize right ventricular pressure and reduce right ventricular hypertrophy and muscularization of peripheral pulmonary vessels |
| Zhang et al. (2020) | 2020 | PAH | Human UC-MSCs | UCF | In vivo: 25 μg EV per rat; three times; intravenous administration In vitro: not reported | EVs inhibit hypoxia-induced pulmonary arterial endothelial cell apoptosis, pulmonary arterial smooth muscle cells proliferation, and pulmonary arterioles endothelial-to-mesenchymal transition by upregulating the expression of Wnt5a |
| Liu et al. (2018) | 2018 | PAH | Rat BM-MSCs | UCF | In vivo: 30 μg EV per rat; once; intravenous administration In vitro: not reported | EVs relieve PAH by regulating renin-angiotensin system |
| Hogan et al. (2019) | 2018 | PAH | Human BM-MSCs | Not reported | In vivo: 2×107 EVs per mouse; once; intravenous administration In vitro: 2×107 EVs added to PASMCs in a 6-well plate biweekly on culture days 1, 4, 8, and 11 | EVs relieve PAH by improving mitochondrial function |
| Chen et al. (2014) | 2014 | PAH | Rat BM-MSCs | UCF | In vivo: 30 μg (protein) EVs per rat; on alternate days for 2 weeks; intravenous administration | EVs relieve PAH (without specific mechanisms) |
Therapeutic applications of MSC-derived EVs in chronic lung diseases.
MSC, mesenchymal stem cell; EVs-extracellular vesicles; COPD-chronic obstructive pulmonary disease; UC-umbilical cord; PRKCZ -protein kinase C zeta; TRAF1-tumor necrosis factor receptor associated factor 1; iPSC-induced pluripotent stem cell; ILC2-group 2 innate lymphoid cells; UCF-ultracentrifugation; PBMCs-peripheral blood mononuclear cells; Tregs-regulatory T cells; SOX4-sky box transcription factor 4; DKK1-Dickkopf Wnt signaling pathway inhibitor 1; HuBEC-human basal bronchial epithelial cell; FZD6-frizzled class receptor 6; AMSC-adipose derived mesenchymal stem cell; ATII-alveolar epithelial type II; HBEC-human bronchial epithelial cell; PPAR-peroxisome proliferator-activated receptor; PAH-pulmonary arterial hypertension.
Mechanisms of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Therapeutic Applications of Chronic Respiratory Diseases
Chronic Obstructive Pulmonary Disease
Previous studies have proved the therapeutic role of MSC-EVs in COPD. Maremanda et al.(Maremanda et al., 2019) reported that exosomes from mouse MSCs could relieve cigarette smoke-induced inflammation and mitochondrial dysfunction in mice and human lung epithelial cells. A recent study demonstrated that EVs from human UC-MSCs were able to reduce both peribronchial and perivascular inflammation, and subsequent microarray analysis revealed that EVs significantly regulate multiple known pathways associated with COPD, including TGF-β receptor signaling pathway, IL-4 signaling pathway, and TNF alpha NF-kB signalling pathway (Ridzuan et al., 2021).
Asthma
The therapeutic role of MSC-EVs in asthma has been investigated both in vitro and in vivo. Dong et al. (Dong et al., 2021) found that human UC-MSCs derived EVs inhibited inflammation by reshaping macrophage polarization via blocking tumor necrosis factor receptor associated factor 1 (TRAF1). Fang et al. (Fang et al., 2020a) also investigated effects of MSC-EVs on macrophages in asthma disease model, and their research suggested that EVs from human iPSC-MSCs inhibited the recruitment and polarization of lung macrophages in mice with allergic airway inflammation. Another study by Fang et al. (Fang et al., 2020b) indicated that MSC-EVs prevented group 2 innate lymphoid cells (ILC2)-dominant allergic airway inflammation in mice, and the anti-inflammatory effect might contribute from transferred miR-146a-5p in MSC-EVs. EVs from human BM-MSCs might also have a therapeutic effect on asthma. Du et al. (Du et al., 2018) revealed that human BM-MSCs derived EVs upregulated IL-10 and TGF-β1 in peripheral blood mononuclear cells (PBMCs), and promoted proliferation, immune-suppression capacity of regulatory T cells (Tregs).
Pulmonary Fibrosis
A growing number of studies have demonstrated that MSC-EVs also play a therapeutic role in pulmonary fibrosis. Xu et al. (Xu et al., 2020) indicated that human UC-MSCs derived EVs could decrease collagen I and fibronectin, and improve pulmonary function. Two Chinese studies proved that EVs from rat BM-MSCs and human UC-MSCs reversed epithelial mesenchymal transition, and the inhibition effect might be related to Wnt/β-catenin signaling and TGF-β1/Smad2/3 pathway (Yang et al., 2020; Zhang et al., 2021).
Three studies indicated MSC-EVs inhibited pulmonary fibrosis by transferring microRNAs. Zhou et al. (Zhou et al., 2021) found that EVs from human BM-MSCs blocked fibroblast activation and suppressed SOX4, DKK1 expression by transferring miR-186. Human BM-MSCs derived EVs could also suppress the fibroblast proliferation by downregulating FZD6 expression via carrying miR‐29b‐3p (Wan et al., 2020). And Gao et al. (Gao et al., 2020) reported that EVs from rat adipose derived mesenchymal stem cells (AMSCs) inhibited TGF-bRI by transferring let-7d-5p in alveolar epithelial cells. MSC-EVs also transferred protein to relieve pulmonary fibrosis. One study by Villamizar et al. (Villamizar et al., 2021) illustrated that EVs from human BM-MSCs were able to deliver a packaged zinc finger activator to human basal bronchial epithelial cells (HuBECs) and activate cystic fibrosis transmembrane conductance regulator (CFTR).
Furthermore, human lung MSC-EVs could upregulate PPARγ, a transcription factor controlling anti-inflammatory and antioxidant mechanisms via NF-κB and HO-1, and prevent cystic fibrosis in vitro (Zulueta et al., 2018).
Pulmonary Arterial Hypertension
Previous studies also investigated the role of MSC-EVs in treating PAH, and the main source of EVs is BM-MSCs. Both rat BM MSC-EVs and human BM MSC-EVs demonstrated therapeutic effects on PAH disease models (Chen et al., 2014; Liu et al., 2018; Hogan et al., 2019), and involved mechanisms included regulating renin-angiotensin system and improving mitochondrial function. Besides, Klinger et al. (Klinger et al., 2020) found that MSC-EVs decreased lung macrophages, increased the ratio of M2/M1 macrophages, normalized right ventricular pressure, and reduced right ventricular hypertrophy and muscularization of peripheral pulmonary vessels. And EVs originated from human UC-MSCs could inhibit hypoxia-induced pulmonary arterial endothelial cell apoptosis, pulmonary arterial smooth muscle cells proliferation, and pulmonary arterioles endothelial-to-mesenchymal transition by upregulating the expression of Wnt5a (Zhang et al., 2020).
Mechanisms of MSC-EVs in chronic respiratory diseases are summarized in Figure 1.
FIGURE 1
Mechanisms of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in treating chronic respiratory diseases. Sources of MSC-EVs: umbilical cord, bone marrow, adipose tissue and induced pluripotent stem cells (iPSCs); Isolation methods: ultracentrifugation (UCF), exosome extraction kits and anion-exchange chromatography; Treatment routes: intratracheal delivery and intravenous administration; Diseases: chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis and pulmonary arterial hypertension (PAH).
Conclusions and Future Directions
Collectively, emerging findings reveal that MSC-EVs may serve as a novel cell-free-based therapy for chronic respiratory diseases, including COPD, asthma, pulmonary fibrosis, and pulmonary arterial hypertension. Bone marrow and umbilical cord are main sources of MSC-EVs in treating chronic respiratory diseases, while adipose tissue, lung, and induced pluripotent stem cells are also applied. Isolation methods of MSC-EVs in treating chronic respiratory diseases involve ultracentrifugation, exosome extraction kits and anion-exchange chromatography. As for treatment routes of MSC-EVs, intratracheal delivery and intravenous administration are most widely used. Current studies suggest that MSC-EVs are able to transfer microRNAs and protein to target cells and further magnify the therapeutic effects. However, existing studies have not compared treatment effects among MSC-EVs from different sources (umbilical cord, bone marrow, adipose tissue and induced pluripotent stem cells) or types (apoptotic bodies, microvesicles and exosomes), which highly prompt future studies to address this item. Novel administration routes of MSC-EVs, such as nebulized inhalation, are also worthy of attention so as to improve the safety and effectiveness of MSC-EVs in the treatment of chronic respiratory diseases. Moreover, future studies through nucleic acid sequencing and proteomics are still warranted to reveal internal components of MSC-EVs from various sources and explicit mechanisms of MSC-EVs treatment on different chronic respiratory disease models.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by National Natural Science Foundation of China (No. 81873410, No. 81800043, and No.82070049), and Natural Science Foundation of Hunan Province (No.2020JJ5818).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
MSCmesenchymal stem cell; EVs-extracellular vesicles; COPD-chronic obstructive pulmonary disease; UC-umbilical cord; PRKCZ -protein kinase C zeta; TRAF1-tumor necrosis factor receptor associated factor 1; iPSC-induced pluripotent stem cell; ILC2-group 2 innate lymphoid cells; UCF-ultracentrifugation; PBMCs-peripheral blood mononuclear cells; Tregs-regulatory T cells; SOX4-sky box transcription factor 4; DKK1-Dickkopf Wnt signaling pathway inhibitor 1; HuBEC-human basal bronchial epithelial cell; FZD6-frizzled class receptor 6; AMSC-adipose derived mesenchymal stem cell; ATII-alveolar epithelial type II; HBEC-human bronchial epithelial cell; PPAR-peroxisome proliferator-activated receptor; PAH-pulmonary arterial hypertension.
References
1
AhnS. Y.ParkW. S.KimY. E.SungD. K.SungS. I.AhnJ. Y.et al (2018). Vascular Endothelial Growth Factor Mediates the Therapeutic Efficacy of Mesenchymal Stem Cell-Derived Extracellular Vesicles against Neonatal Hyperoxic Lung Injury. Exp. Mol. Med.50 (4), 1–12. 10.1038/s12276-018-0055-8
2
BertassoliB. M.Assis NetoA. C. d.OliveiraF. D. d.ArroyoM. A. M.FerrãoJ. S. P.SilvaJ. B. d.et al (2013). Mesenchymal Stem Cells: Emphasis in Adipose Tissue. Braz. Arch. Biol. Technol.56 (4), 607–617. 10.1590/s1516-89132013000400011
3
BorgesF. T.ReisL. A.SchorN. (2013). Extracellular Vesicles: Structure, Function, and Potential Clinical Uses in Renal Diseases. Braz. J. Med. Biol. Res.46 (10), 824–830. 10.1590/1414-431x20132964
4
ChenJ.-y.AnR.LiuZ.-j.WangJ.-j.ChenS.-z.HongM.-m.et al (2014). Therapeutic Effects of Mesenchymal Stem Cell-Derived Microvesicles on Pulmonary Arterial Hypertension in Rats. Acta Pharmacol. Sin35 (9), 1121–1128. 10.1038/aps.2014.61
5
ChenY.-T.MiaoK.ZhouL.XiongW.-N. (2021). Stem Cell Therapy for Chronic Obstructive Pulmonary Disease. Chin. Med. J.134 (13), 1535–1545. 10.1097/cm9.0000000000001596
6
de FariaC. A.de las Heras KozmaR.StessukT.Ribeiro-PaesJ. T. (2012). Experimental Basis and New Insights for Cell Therapy in Chronic Obstructive Pulmonary Disease. Stem Cel Rev Rep8 (4), 1236–1244. 10.1007/s12015-012-9410-7
7
DongB.WangC.ZhangJ.ZhangJ.GuY.GuoX.et al (2021). Exosomes from Human Umbilical Cord Mesenchymal Stem Cells Attenuate the Inflammation of Severe Steroid-Resistant Asthma by Reshaping Macrophage Polarization. Stem Cel Res Ther12 (1), 12. 10.1186/s13287-021-02244-6
8
DuY.-m.ZhuansunY.-x.ChenR.LinL.LinY.LiJ.-g. (2018). Mesenchymal Stem Cell Exosomes Promote Immunosuppression of Regulatory T Cells in Asthma. Exp. Cel Res.363 (1), 114–120. 10.1016/j.yexcr.2017.12.021
9
EirinA.LermanL. O. (19792021). Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles for Chronic Kidney Disease: Are We There yet?Hypertension78 (2), 261–269. 10.1161/hypertensionaha.121.14596
10
FangS.-B.ZhangH.-Y.MengX.-C.WangC.HeB.-X.PengY.-Q.et al (2020). Small Extracellular Vesicles Derived from Human MSCs Prevent Allergic Airway Inflammation via Immunomodulation on Pulmonary Macrophages. Cell Death Dis11 (6). 10.1038/s41419-020-2606-x
11
FangS. B.ZhangH. Y.WangC.HeB. X.LiuX. Q.MengX. C.et al (2020). Small Extracellular Vesicles Derived from Human Mesenchymal Stromal Cells Prevent Group 2 Innate Lymphoid Cell‐dominant Allergic Airway Inflammation through Delivery of miR‐146a‐5p. J. extracellular vesicles9 (1), 1723260. 10.1080/20013078.2020.1723260
12
Forum of International Respiratory Societies (2017). The Global Impact of Respiratory Disease. 2nd edn. Sheffield: European Respiratory SocietyAvailable at: https://wwwwhoint/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf (Accessed Oct 24th, 2021).
13
FuS.ZhangY.LiY.LuoL.ZhaoY.YaoY. (2020). Extracellular Vesicles in Cardiovascular Diseases. Cell Death Discov.6 (1). 10.1038/s41420-020-00305-y
14
GaoY.SunJ.DongC.ZhaoM.HuY.JinF. (2020). Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Alleviate PM2.5-Induced Lung Injury and Pulmonary Fibrosis. Med. Sci. Monit.26, 26. 10.12659/msm.922782
15
GemollT.StrohkampS.RozanovaS.RöderC.HartwigS.KalthoffH.et al (2020). Protein Profiling of Serum Extracellular Vesicles Reveals Qualitative and Quantitative Differences after Differential Ultracentrifugation and ExoQuick Isolation. Jcm9 (5), 1429. 10.3390/jcm9051429
16
HerrmannI. K.WoodM. J. A.FuhrmannG. (2021). Extracellular Vesicles as a Next-Generation Drug Delivery Platform. Nat. Nanotechnol.16 (7), 748–759. 10.1038/s41565-021-00931-2
17
HoganS. E.Rodriguez SalazarM. P.CheadleJ.GlennR.MedranoC.PetersenT. H.et al (2019). Mesenchymal Stromal Cell-Derived Exosomes Improve Mitochondrial Health in Pulmonary Arterial Hypertension. Am. J. Physiology-Lung Cell Mol. Physiol.316 (5), L723–L737. 10.1152/ajplung.00058.2018
18
JalaliE.RabieeM. (2016). Adipose Tissue Derived Mesenchymal Stem Cells. Iioab J.7 (8), 112–118.
19
KhatriM.RichardsonL. A.MeuliaT. (2018). Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Influenza Virus-Induced Acute Lung Injury in a Pig Model. Stem Cel Res Ther9 (1), 17. 10.1186/s13287-018-0774-8
20
KimD.-k.NishidaH.AnS. Y.ShettyA. K.BartoshT. J.ProckopD. J. (2016). Chromatographically Isolated CD63+CD81+ Extracellular Vesicles from Mesenchymal Stromal Cells rescue Cognitive Impairments after TBI. Proc. Natl. Acad. Sci. USA113 (1), 170–175. 10.1073/pnas.1522297113
21
KlingerJ. R.PereiraM.Del TattoM.BrodskyA. S.WuK. Q.DoonerM. S.et al (2020). Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats. Am. J. Respir. Cel Mol Biol62 (5), 577–587. 10.1165/rcmb.2019-0154OC
22
LamaV. N.SmithL.BadriL.FlintA.AndreiA.-C.MurrayS.et al (2007). Evidence for Tissue-Resident Mesenchymal Stem Cells in Human Adult Lung from Studies of Transplanted Allografts. J. Clin. Invest.117 (4), 989–996. 10.1172/jci29713
23
LasdaE.ParkerR. (2016). Circular RNAs Co-precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance. PloS one11 (2), e0148407. 10.1371/journal.pone.0148407
24
LiY.ZhaoJ.YuS.WangZ.HeX.SuY.et al (2019). Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and lncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. Clin. Chem.65 (6), 798–808. 10.1373/clinchem.2018.301291
25
LinaresR.TanS.GounouC.ArraudN.BrissonA. R. (2015). High-speed Centrifugation Induces Aggregation of Extracellular Vesicles. J. extracellular vesicles4, 29509. 10.3402/jev.v4.29509
26
LiuZ.LiuJ.XiaoM.WangJ.YaoF.ZengW.et al (2018). Mesenchymal Stem Cell-Derived Microvesicles Alleviate Pulmonary Arterial Hypertension by Regulating Renin-Angiotensin System. J. Am. Soc. Hypertens.12 (6), 470–478. 10.1016/j.jash.2018.02.006
27
LivshitsM. A.KhomyakovaE.EvtushenkoE. G.LazarevV. N.KuleminN. A.SeminaS. E.et al (2015). Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a Commonly Used Protocol. Sci. Rep.5, 17319. 10.1038/srep17319
28
MaremandaK. P.SundarI. K.RahmanI. (2019). Protective Role of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Cigarette Smoke-Induced Mitochondrial Dysfunction in Mice. Toxicol. Appl. Pharmacol.385, 114788. 10.1016/j.taap.2019.114788
29
Momen-HeraviF. (2017). Isolation of Extracellular Vesicles by Ultracentrifugation. In Methods in Molecular Biology, 1660. Clifton, NJ, 25–32. 10.1007/978-1-4939-7253-1_3
30
MonselA.ZhuY.-g.GennaiS.HaoQ.HuS.RoubyJ.-J.et al (2015). Therapeutic Effects of Human Mesenchymal Stem Cell-Derived Microvesicles in Severe Pneumonia in Mice. Am. J. Respir. Crit. Care Med.192 (3), 324–336. 10.1164/rccm.201410-1765OC
31
PucciF.HamiltonN.ClaudioN.ArmstrongR. (2021). Tumor-immune Communication via Extracellular Vesicles. Cancer Immunol. Res.9 (2).
32
RidzuanN.ZakariaN.WideraD.SheardJ.MorimotoM.KiyokawaH.et al (2021). Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate Airway Inflammation in a Rat Model of Chronic Obstructive Pulmonary Disease (COPD). Stem Cel Res Ther12 (1), 12. 10.1186/s13287-020-02088-6
33
SergejevaS.HoshinoH.YoshiharaS.KashimotoK.LötvallJ.LindénA. (2004). A Synthetic VIP Peptide Analogue Inhibits Neutrophil Recruitment in Rat Airways In Vivo. Regul. peptides117 (2), 149–154. 10.1016/j.regpep.2003.10.002
34
ShaoH.ImH.CastroC. M.BreakefieldX.WeisslederR.LeeH. (2018). New Technologies for Analysis of Extracellular Vesicles. Chem. Rev.118 (4), 1917–1950. 10.1021/acs.chemrev.7b00534
35
ShiM. m.YangQ. y.MonselA.YanJ. y.DaiC. x.ZhaoJ. y.et al (2021). Preclinical Efficacy and Clinical Safety of Clinical‐grade Nebulized Allogenic Adipose Mesenchymal Stromal Cells‐derived Extracellular Vesicles. J. extracellular vesicles10 (10), e12134. 10.1002/jev2.12134
36
SorianoJ. B.KendrickP. J.PaulsonK. R.GuptaV.VosT.AbramsE. M.et al (2020). Prevalence and Attributable Health burden of Chronic Respiratory Diseases, 1990-2017: a Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med.8 (6), 585–596. 10.1016/S2213-2600(20)30105-3
37
ThéryC.WitwerK. W.AikawaE.AlcarazM. J.AndersonJ. D.AndriantsitohainaR.et al (2018). Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): a Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. J. Extracell Vesicles7 (1), 1535750. 10.1080/20013078.2018.1535750
38
TranP. H. L.DuanW.LeeB.-J.TranT. T. D. (2020). Current Perspectives on Delivery Systems Using Extracellular Vesicles in Neurological Disease. Cpd26 (7), 764–771. 10.2174/1381612826666200102125847
39
VagnerT.ChinA.MariscalJ.BannykhS.EngmanD. M.Di VizioD. (2019). Protein Composition Reflects Extracellular Vesicle Heterogeneity. Proteomics19 (8), 1800167. 10.1002/pmic.201800167
40
VilacaA.SansonettiM.FernandesH.de WindtL.FerreiraL. (2021). Extracellular Vesicles as lncRNA-H19 Carriers to the Cardiovascular System. Eur. J. Clin. Invest.51, 108–109.
41
VillamizarO.WatersS. A.ScottT.GrepoN.JaffeA.MorrisK. V. (2021). Mesenchymal Stem Cell Exosome Delivered Zinc Finger Protein Activation of Cystic Fibrosis Transmembrane Conductance Regulator. J. extracellular vesicles10 (3), 10. 10.1002/jev2.12053
42
VuL. T.GongJ.PhamT. T.KimY.LeM. T. N. (2020). microRNA Exchange via Extracellular Vesicles in Cancer. Cell Prolif53 (11), 53. 10.1111/cpr.12877
43
WanX.ChenS.FangY.ZuoW.CuiJ.XieS. (2020). Mesenchymal Stem Cell‐derived Extracellular Vesicles Suppress the Fibroblast Proliferation by Downregulating FZD6 Expression in Fibroblasts via micrRNA‐29b‐3p in Idiopathic Pulmonary Fibrosis. J. Cel Physiol235 (11), 8613–8625. 10.1002/jcp.29706
44
WeissA. R. R.DahlkeM. H. (2019). Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front. Immunol.10, 1191. 10.3389/fimmu.2019.01191
45
World Health OrganizationChronic Respiratory Diseases. Available at: https://www.who.int/health-topics/chronic-respiratory-diseases#tab=tab_1 (Accessed Oct 24th, 2021).
46
XuC.ZhaoJ.LiQ.HouL.WangY.LiS.et al (2020). Exosomes Derived from Three-Dimensional Cultured Human Umbilical Cord Mesenchymal Stem Cells Ameliorate Pulmonary Fibrosis in a Mouse Silicosis Model. Stem Cel Res Ther11 (1), 11. 10.1186/s13287-020-02023-9
47
YangJ.HuH.ZhangS.JiangL.ChengY.XieH.et al (2020). Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Alleviate Pulmonary Fibrosis in Mice by Inhibiting Epithelial-Mesenchymal Transition. Nan Fang Yi Ke Da Xue Xue BaoMEDLINE40 (7), 98832895166–98832895994. 10.12122/j.issn.1673-4254.2020.07.11
48
YuanX.LiD.ChenX.HanC.XuL.HuangT.et al (2017). Extracellular Vesicles from Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells (hiPSC-MSCs) Protect against Renal Ischemia/reperfusion Injury via Delivering Specificity Protein (SP1) and Transcriptional Activating of Sphingosine Kinase 1 and Inhibiting Necroptosis. Cel Death Dis8 (12), 3200. 10.1038/s41419-017-0041-4
49
ZhangE.GengX.ShanS.LiP.LiS.LiW.et al (2021). Exosomes Derived from Bone Marrow Mesenchymal Stem Cells Reverse Epithelial-Mesenchymal Transition Potentially via Attenuating Wnt/β-Catenin Signaling to Alleviate Silica-Induced Pulmonary Fibrosis. Toxicol. Mech. Methods31 (9), 655–666. 10.1080/15376516.2021.1950250
50
ZhangS.LiuX.GeL. L.LiK.SunY.WangF.et al (2020). Mesenchymal Stromal Cell-Derived Exosomes Improve Pulmonary Hypertension through Inhibition of Pulmonary Vascular Remodeling. Respir. Res.21 (1), 21. 10.1186/s12931-020-1331-4
51
ZhouJ.LinY.KangX.LiuZ.ZhangW.XuF. (2021). microRNA-186 in Extracellular Vesicles from Bone Marrow Mesenchymal Stem Cells Alleviates Idiopathic Pulmonary Fibrosis via Interaction with SOX4 and DKK1. Stem Cel Res Ther12 (1), 12. 10.1186/s13287-020-02083-x
52
ZuluetaA.ColomboM.PeliV.FalleniM.TosiD.RicciardiM.et al (2018). Lung Mesenchymal Stem Cells-Derived Extracellular Vesicles Attenuate the Inflammatory Profile of Cystic Fibrosis Epithelial Cells. Cell Signal.51, 110–118. 10.1016/j.cellsig.2018.07.015
Summary
Keywords
mesenchymal stem cell, extracellular vesicle, chronic respiratory disease, therapy, microRNA
Citation
Ma Y, Liu X, Long Y and Chen Y (2022) Emerging Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Chronic Respiratory Diseases: An Overview of Recent Progress. Front. Bioeng. Biotechnol. 10:845042. doi: 10.3389/fbioe.2022.845042
Received
29 December 2021
Accepted
31 January 2022
Published
25 February 2022
Volume
10 - 2022
Edited by
Hong Yang, Tianjin Medical University, China
Reviewed by
Zhigang Cai, Tianjin Medical University, China
Wenjun Mao, The affiliated Wuxi People’s Hospital of Nanjing Medical University, China
Updates
Copyright
© 2022 Ma, Liu, Long and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yan Chen, chenyan99727@csu.edu.cn; Yingjiao Long, longyingjiao@csu.edu.cn
This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.